Katherine Rittenbach
Positions
Assistant Professor (Research)
Cumming School of Medicine, Department of Psychiatry
Full Member
Mathison Centre for Mental Health Research and Education
Full Member
Hotchkiss Brain Institute
Full Member
O'Brien Institute for Public Health
Contact information
Background
Educational Background
PhD Psychiatry, University of Alberta, 2007
BA Chemistry, Rice University,
Research
Areas of Research
My research has spanned a large variety of mental health and substance use topics over the last decade.
My undergrad and PhD work focused on analytical chemistry. The focus of my dissertation was the analysis of metabolism by CYP P450 enzymes on potential neuroprotective substances. My work really focused on neurochemicals and brain function in psychiatry.
Following completion of my PhD, I moved into clinical research, designing and managing multiple national Health Canada approved double-blind, placebo-controlled, randomized clinical studies. This work, combined with several years on the HREB panel at the University of Alberta form the foundation of my expertise in Clinical Studies (RCT and others).
Since 2014, I have focused on health system and administrative data research in mental health and substance use. The administrative data research has included studies on the impact of cannabis legalization in Canada and the possibility of using administrative data to investigate treatment resistant depression. The health system research has included being a co-lead on the creation of Canadian Guidelines for Take Home Naloxone Community Programs, work to understand the experiences of First Nation Peoples in Alberta Emergency Rooms, and a project studying the impact of rooming in for parent/baby dyads where the baby was exposed to substances prior to birth.
My interest and focus currently is on using technology to create a system dynamic model of the substance use treatment system in Calgary. I will use administrative data to create the model, investigating how patients flow through the system. Then I will overlay information from people with lived/living experience in the system, working to determine the ‘why’ behind the patient flow along with outcomes. Ultimately, I want to examine marginalized groups and improve their experience and outcomes from the system.
More Information
Complete Bibliography:
https://www.ncbi.nlm.nih.gov/myncbi/collections/mybibliography/
Selected Publications:
Substance Use:
Ferguson M, Rittenbach K, Leece P, Adams A, Ali F, Elton-Marshall T, Burmeister C, Brothers TD, Medley A, Chisel P, Strike C, Ng J, Lorenzetti DL, Gallant K, Buxton JA (2023) Guidance on take-home naloxone distribution and use by community overdose responders in Canada CMAJ 195(33): E1112-E1123 doi: 10.1503/cmaj.230128
Ferguson M, Medley A, Rittenbach K, Brothers TD, Strike C, Ng J, Leece P, Elton-Marshall T, Ali F, Lorenzetti D, Baxton JA (2022) Priority setting for Canadian take-home naloxone best practice guideline development. An adapted online Delphi method. Harm Reduction Journal 19(1):71 doi: 10.1186/s12954-022-00650-4
Brophy H, Dyson M, Rittenbach K (2023) Concept Analysis of Recovery from Substance Use International Journal of Mental Health Nursing 32(1): 117-127 doi: 10.1111/imm.13066
Wine O, McNeil D, Kromm SK, Foss K, Caine V, Clarke D, Day N, Johnson DW, Rittenbach K, Wood S, Hicks M (2023) The Alberta Neonatal Abstinence Syndrome Mother-Baby Care ImprovEmeNT (NASCENT) program: protocol for a stepped wedge cluster randomized trial of a hospital-level Neonatal Abstinence Syndrome rooming-in intervention BMC Health Services Research 23(1):448 doi: 10.1186/s12913-023-09440-5
Milaney K, Haines-Saah R, Farkas B, Egunsola O, Mastikhina L, Brown S, Lorenzetti DL, Hansen B, McBrien K, Rittenbach K, Hill L, O’Gorman C, Doig C, Cabaj J, Stokvis C, Clement F (2022) A scoping review of opioid harm reduction interventions designed for equity-deserving populations Lancet Public Health 12, doi:10.1016/j.lana.2022.100271
First Nations Peoples experience in Alberta Emergency Departments
McLane P, Bill L, Healy B, Barnabe C, Big Plume T, Bird A, Colquhoun A, Holroyd BR, Javier K, Louis E, Rittenbach K, Curtin KD, Fitzpatrick KM, Mackey L, MacLean D, Rosychuk R (2024) Leaving emergency departments without completing treatment among First Nations and non-First Nations patients in Alberta: a mixed-methods study CMAJ April 22;196: E510-23 doi: 10.1503/cmaj.231019
McLane P, Mackey L, Holroyd BR, Fitzpatrick K, Healy C, Rittenbach K, Big Plume T, Bill L, Bird A, Healy B, Janvier K, Louis E, Barnabe C. (2022) Impacts of Racism on First Nations Patients' Emergency Care: Results of a Thematic Analysis of Healthcare Provider Interviews in Alberta, Canada. BMC Health Services Research 22(1): 804 doi: 10.1186/s12913-022-08129-5
McLane P, Barnabe C, Mackey L, Bill L, Rittenbach K, Holroyd B, Bird A, Healy B, Janvier K, Louis E, Rosychuk R. (2021) First Nations status and emergency department triage scores in the Canadian province of Alberta: a retrospective cohort study using linked administrative data. CMAJ 194(2) E37-E45, doi.org/10.1503/cmaj210779
Cannabis
Soos B, Garies S, Cornect-Benoit A, Montgomery L, Sharpe H, Rittenbach K, Manca D, Cuerksen K, Forst B, Drummond N (2023) Documenting cannabis use in primary care: a descriptive cross-sectional study using electronic medical record data in Alberta, Canada BMC Research Notes 16(1):9 doi: 10.1186/s13104-023-06274-6
Kim C, Chum A, Nielsen A, Allin S, Penney TL, Rittenbach K, MacMaster FP, O’Campo P (2022) Associations between recreational cannabis legalization and cannabis – related emergency department visits by age, gender, and geographic status in Ontario, Canada: An interrupted time series study PLoS One 17(10): e0268718 doi: 10.1371/journal.pone.0268718
Kim C, Chum A, Nielsen A, MacMaster F, Rittenbach K, Allin S, O’Campo P, Kirst M, Hamilton H (2023) Cannabis Legalization and cannabis-Related Hospitalizations in Ontario, Canada Canadian Journal of Psychiatry 68(1): 67-70 doi: 10.1177/07067437221114785
Andrews CN, Rehak R, Woo M, Walker I, Ma C, Forbes N, Rittenbach K, Hathaway J, Wilsack L, Liu A, Nasser Y, Sharkey KA (2022) Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence Aliment Pharmacol Ther 56(11-12): 1532 – 1542 doi: 10.1111/apt.17265
Williamson N, Hathaway J, Jahrig J, Vik S, Rittenbach K (2022) Cannabis use and concern among clients seeking substance misuse treatment: demographics, comorbidities, and service utilization patterns pre-legalization (2012-2018) Canadian Journal of Addiction 13(1): 19-26, doi: 10.1097/CXA.0000000000000136
Are you the profile owner?
Login to edit.